Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review
10.3969/j.issn.1001-5256.2022.11.005
- VernacularTitle:基础慢性肝脏疾病对接受免疫检查点抑制剂治疗的肿瘤患者的疗效及安全性的影响
- Author:
Dan LIU
1
;
Tiantian YAO
1
;
Yuhan ZHANG
1
;
Guiqiang WANG
1
;
Yan WANG
1
Author Information
1. Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
- Publication Type:Discussions by Experts
- Keywords:
Liver Diseases;
Neoplasms;
Immune Checkpoint Inhibitors;
Hepatitis B
- From:
Journal of Clinical Hepatology
2022;38(11):2457-2461
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) have recently been approved for the treatment of cancer, and the number of cancer patients with chronic liver disease (CLD) receiving ICIs is growing rapidly. However, whether CLD affects the efficiency and safety of ICIs is becoming a research focus. This review summarizes the efficiency and safety of ICIs in cancer patients with CLD, including chronic viral hepatitis, non-alcoholic fatty liver disease, autoimmune liver disease, and cirrhosis. Specifically, data on hepatitis B virus reactivation of patients with chronic hepatitis B after ICIs treatment were reviewed, which may help to perfect and standardize the guidelines of treatment and following-up for ICIs in CLD patients.
